{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T05:29:25Z","timestamp":1795152565650,"version":"4.10.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Incyte Corporation","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-017-0417-z","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T13:14:08Z","timestamp":1487769248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":378,"title":["Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial"],"prefix":"10.1186","volume":"10","author":[{"name":"for the COMFORT-I investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W. N.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott F.","family":"Winton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Jimmie H.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat O.","family":"Arcasoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"417_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.","journal-title":"BMC Cancer"},{"key":"417_CR3","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/leu.2011.161","volume":"25","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25:1834\u20139.","journal-title":"Leukemia"},{"key":"417_CR4","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995\u20133001.","journal-title":"J Clin Oncol"},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","volume":"120","author":"V Gupta","year":"2012","unstructured":"Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120:1367\u201379.","journal-title":"Blood"},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"417_CR7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1038\/bcj.2015.90","volume":"5","author":"P Guglielmelli","year":"2015","unstructured":"Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, et al. Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis. Blood Cancer J. 2015;5:e360.","journal-title":"Blood Cancer J"},{"key":"417_CR9","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.3324\/haematol.2015.138958","volume":"101","author":"J Asp","year":"2016","unstructured":"Asp J, Andreasson B, Hansson U, Wasslavik C, Abelsson J, Johansson P, et al. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome. Haematologica. 2016;101:e129\u201332.","journal-title":"Haematologica"},{"key":"417_CR10","unstructured":"JAKAFI\u00ae (ruxolitinib). Full Prescribing Information, Incyte Corporation. Wilmington, DE, 2016. Available at: \n                    https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf\n                    \n                  . Accessed 8 Aug 2016."},{"key":"417_CR11","volume-title":"EU Summary of Product Characteristics","author":"JAKAVI\u00ae (ruxolitinib)","year":"2015","unstructured":"JAKAVI\u00ae (ruxolitinib). EU Summary of Product Characteristics. Basel, Switzerland: Novartis Pharmaceuticals Corporation; 2015."},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol. 2013;161:508\u201316.","journal-title":"Br J Haematol"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479\u201388.","journal-title":"Haematologica"},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047\u201353.","journal-title":"Blood"},{"key":"417_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701\u20137.","journal-title":"Leukemia"},{"key":"417_CR18","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: \n                    http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf\n                    \n                  . Accessed 18 Oct 2016."},{"key":"417_CR19","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","volume":"15","author":"RA Mesa","year":"2015","unstructured":"Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, et al. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015;15:214\u201321. e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126:1551\u20134.","journal-title":"Blood"},{"key":"417_CR22","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u201317.","journal-title":"Blood"},{"key":"417_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quint\u00e1s-Cardama","year":"2011","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10:127\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"417_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1756-8722-6-79","volume":"6","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6:79.","journal-title":"J Hematol Oncol"},{"key":"417_CR25","series-title":"Blood (ASH Annual Meeting Abstracts)","volume-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib: an exploratory analysis of the COMFORT studies","author":"V Gupta","year":"2015","unstructured":"Gupta V, Harrison CN, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib: an exploratory analysis of the COMFORT studies, Blood (ASH Annual Meeting Abstracts). 2015. 120:abstract 1604."},{"key":"417_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"417_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clml.2013.01.001","volume":"13","author":"A Quintas-Cardama","year":"2013","unstructured":"Quintas-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:315\u20138. e2.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0417-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-017-0417-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0417-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T21:31:38Z","timestamp":1616448698000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0417-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0417-z","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.21203\/rs.3.rs-353518\/v1","asserted-by":"subject"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]},"assertion":[{"value":"14 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}